You are here: Industry Insights > Janssen

News List

Genmab, Janssen Partner for Next-Gen CD38 Antibody contractpharma
June 20, 2019
To collaborate on HexaBody-CD38, a next-generation CD38 antibody product incorporating Genmab's HexaBody technology.
Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials pharmaceutical-technology
June 19, 2019
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults with moderate to severe psoriatic arthritis.
Janssen presents positive Darzalex results at ASCO pharmatimes
June 03, 2019
Janssen Oncology has announced key data on Darzalex (daratumumab) for multiple myeloma at this year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
New data highlights value of Janssen’s Spravato pharmatimes
May 29, 2019
New data has illustrated the value of Janssen’s oral antidepressant Spravato (esketamine) CIII nasal spray for treatment-resistant depression (TRD).
Janssen’s Invokana secures FDA priority review status pharmaceutical-technology
May 24, 2019
Janssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney disease (CKD).
Wellspring Biosciences, Janssen Receive IND Clearance contractpharma
May 20, 2019
anssen Biotech will conduct the Phase I trial for ARS-3248, a small molecule KRAS G12C inhibitor.
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists firstwordpharma
May 09, 2019
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist's first-in-class ...
Janssen’s bladder cancer drug Balversa receives FDA nod pharmaceutical-technology
April 22, 2019
Janssen Pharmaceutical has received the US Food and Drug Administration (FDA) approval for the drug Balversa (erdafitinib) to treat adults with locally advanced or metastatic urothelial carcinoma (mUC).
SomaLogic & Janssen Enter Agreement contractpharma
April 15, 2019
SomaLogic to analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify & validate protein biomarkers for use to treat diseases...
Immunomedics Announces Promotion Agreement With Janssen for Erdafitinib in the U.S. firstwordpharma
April 09, 2019
Under the terms of the agreement, Immunomedics' sales team will provide product detailing from the launch……

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page